Alex Lugovskoy, CEO of Diagonal Therapeutics, aims to develop antibodies that activate targets, rather than just inhibit cellular functions. Using computational and experimental techniques, the startup focuses on binding combinations to yield desired effects. Diagonal’s platform, developed over two years, includes a lead program for a rare bleeding disorder without FDA-approved therapies. Their technology, which can produce working agonist antibodies in under eight months, has shown promising results in preclinical research for hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension. The startup’s Series A financing from various investors will mainly support the HHT program, with plans to expand to rare cardiovascular diseases and potential biopharma partnerships in the future.
Source link
Diagonal Therapeutics’ New Slant Attracts $128M to Reactivate Antibody Drug R&D
